141412-60-4

Basic information

• Product Name: 1,4-DIFLUORO-2-METHYL-5-NITROBENZENE
• Synonyms: 1,4-DIFLUORO-2-METHYL-5-NITROBENZENE;2,5-Difluoro-4-methylnitrobenzene;2，5-Difluoro-4-nitrotoluene;2,5-Difluoro-4-methyinitrobenzene;2,5-Difluoro-4-methylnitrobenzene, 1,4-Difluoro-2-methyl-5-nitrobenzene;1,4-Difluoro-2-Methyl-5-nitrobenzene[2,5-difluoro-4-nitrotoluene];Benzene, 1,4-difluoro-2-methyl-5-nitro-
• CAS NO: 141412-60-4
• Molecular Formula: C₇H₅F₂NO₂
• Molecular Weight: 173.12
• Product Categories: Halogen toluene
• Mol File: 141412-60-4.mol
• Article Data: 7

Chemical Properties

• Melting Point: 25 °C
• Boiling Point: 251 ºC
• Flash Point: 121 ºC
• Appearance: /
• Density: 1.374
• Vapor Pressure: 0.0332mmHg at 25°C
• Refractive Index: 1.508
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 1,4-DIFLUORO-2-METHYL-5-NITROBENZENE(CAS DataBase Reference)
• NIST Chemistry Reference: 1,4-DIFLUORO-2-METHYL-5-NITROBENZENE(141412-60-4)
• EPA Substance Registry System: 1,4-DIFLUORO-2-METHYL-5-NITROBENZENE(141412-60-4)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 141412-60-4(Hazardous Substances Data)

Usage

InChI:InChI=1/C7H5F2NO2/c1-4-2-6(9)7(10(11)12)3-5(4)8/h2-3H,1H3

Upstream product

• 452-67-5 1,4-difluoro-2-methylbenzene 

Downstream Products

• 932374-51-1 1,1-dimethylethyl 4-(5-fluoro-6-methyl-2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)-1-piperidine-carboxylate 
• 182880-71-3 1-fluoro-4-methoxy-2-methyl-5-nitrobenzene 
• 1299488-23-5 2,5-difluoro-4-(piperidin-4-ylmethyl)aniline 
• 1299488-24-6 tert-butyl 4-(4-amino-2,5-difluorobenzyl)piperidine-1-carboxylate 
• 1299488-25-7 2-(4-((4-(4-amino-2,5-difluorobenzyl)piperidin-1-yl)methyl)phenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol 
• 1299488-22-4 tert-butyl 4-(2,5-difluoro-4-nitrobenzylidene)piperidine-1-carboxylate 
• 1299488-21-3 diethyl 2,5-difluoro-4-nitrobenzylphosphonate 
• 1260640-04-7 1-(bromomethyl)-2,5-difluoro-4-nitrobenzene 
• 1299488-20-2 1-(2,5-difluoro-4-((1-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)benzyl)piperidin-4-yl)methyl)phenyl)-3-(2-hydroxy-2-methylpropyl)urea 

Relevant articles and documents

Preparation method of 2,4,5-trifluorophenylacetic acid

The invention belongs to the technical field of preparation of drug intermediates, and discloses a preparation method of 2,4,5-trifluorophenylacetic acid, wherein the preparation method comprises the steps: step 1, reacting raw materials, a quaternary ammonium salt catalyst, sulfolane and potassium fluoride to obtain a first intermediate; step 2, carrying out hydrogenation catalytic reaction on the first intermediate to obtain a second intermediate; step 3, carrying out salt forming reaction on the second intermediate and a fluorinating reagent, quenching, and carrying out diazotization reaction on the second intermediate and a sodium nitrite aqueous solution to obtain diazonium salt; step 4, carrying out high-temperature cracking on the diazonium salt, to obtain 2,4,5-trifluorotoluene; and step 5 to step 7, carrying out halogenation, cyanidation and hydrolysis reactions on 2,4,5-trifluorotoluene in sequence, and thus obtaining 2,4,5-trifluorophenylacetic acid. The raw materials adopted by the method are easy to obtain and low in cost, the yield of the corresponding product obtained in each step is high, and large-scale production of the 2,4,5-trifluorophenylacetic acid is facilitated.

1- (1-CYCLOHEXYL-4-PIPERIDINYL) -1, 3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES WHICH HAVE ACTIVITY ON THE M1 RECEPTOR AND THEIR USE IN MEDICINE

Compounds of formula (I) or a salt thereof are provided, wherein R4, R5, R6, Q and R are as defined in the description. Uses of the compounds as medicaments and in the manufacture of medicaments for treating psychotic disorders and cognitive impairments are disclosed. The invention further discloses pharmaceutical compositions comprising the compounds.

Alkyl, azido, alkoxy, and fluoro-substituted and fused quinoxalinediones

Methods of treating or preventing neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, and surgery, as well as treating neurodegenerative diseases including Alzheimer's disease, amyotrophic lateral sclerosis, Huntington's disease, and Down's syndrome, treating or preventing the adverse consequences of the hyperactivity of the excitatory amino acids, as well as treating anxiety, chronic pain, convulsions, and inducing anesthesia are disclosed by administering to an animal in need of such treatment an alkyl or azido-substituted 1,4-dihydroquinoxaline-2,3-dione or pharmaceutically acceptable salts thereof, which have high binding to the glycine receptor.